A fully human monoclonal antibody with novel binding epitope and excellent neutralizing activity to multiple human IFN-α subtypes: A candidate therapy for systemic lupus erythematosus

References

• Ronnblom L. Potential role of IFN alpha in adult lupus. Arthritis Res Ther 2010; 12 Suppl 1:S3; PMID:20392290; http://dx.doi.org/10.1186/ar2884
   PubMedGoogle Scholar
• Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-39; PMID:18305268; http://dx.doi.org/10.1056/NEJMra071297
   PubMed Web of Science ®Google Scholar
• Eisenberg R. Why can't we find a new treatment for SLE? J Autoimmun 2009; 32:223-30; PMID:19329279; http://dx.doi.org/10.1016/j.jaut.2009.02.006
   PubMed Web of Science ®Google Scholar
• Xiong W, Lahita RG. Novel treatments for systemic lupus erythematosus. Ther Adv Musculoskelet Dis 2011; 3:255-66; PMID:22870484; http://dx.doi.org/10.1177/1759720X11415456
   PubMedGoogle Scholar
• Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Best Pract Res Clin Rheumatol 2005; 19:859-78; PMID:16150407; http://dx.doi.org/10.1016/j.berh.2005.05.006
   PubMed Web of Science ®Google Scholar
• Lavoie TB, Kalie E, Crisafulli-Cabatu S, Abramovich R, DiGioia G, Moolchan K, Pestka S, Schreiber G. Binding and activity of all human alpha interferon subtypes. Cytokine 2011; 56:282-9; PMID:21856167; http://dx.doi.org/10.1016/j.cyto.2011.07.019
   PubMed Web of Science ®Google Scholar
• Krause CD, Pestka S. Evolution of the Class 2 cytokines and receptors, and discovery of new friends and relatives. Pharmacol Ther 2005; 106:299-346; PMID:15922016; http://dx.doi.org/10.1016/j.pharmthera.2004.12.002
   PubMed Web of Science ®Google Scholar
• Weissmann C, Weber H. The Interferon Genes. Progress in Nucleic Acid Research and Molecular Biology 1986; 33:251-300; PMID:3025923
   PubMed Web of Science ®Google Scholar
• Banchereau J, Pascual V. Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 2006; 25:383-92; PMID:16979570; http://dx.doi.org/10.1016/j.immuni.2006.08.010
   PubMed Web of Science ®Google Scholar
• Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197:711-23; PMID:12642603; http://dx.doi.org/10.1084/jem.20021553
   PubMed Web of Science ®Google Scholar
• Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci 2003; 100:2610-5; PMID:12604793; http://dx.doi.org/10.1073/pnas.0337679100
   PubMed Web of Science ®Google Scholar
• Yao Y, Higgs BW, Morehouse C, de Los Reyes M, Trigona W, Brohawn P, White W, Zhang J, White B, Coyle AJ, et al. Development of potential pharmacodynamic and diagnostic markers for Anti-IFN-alpha monoclonal antibody trials in systemic lupus erythematosus. Hum Genomics Proteomics 2009; 2009; pii: 374312; PMID:20948567
   PubMedGoogle Scholar
• Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54:1906-16; PMID:16736505; http://dx.doi.org/10.1002/art.21890
   PubMed Web of Science ®Google Scholar
• Agrawal H, Jacob N, Carreras E, Bajana S, Putterman C, Turner S, Neas B, Mathian A, Koss MN, Stohl W, et al. Deficiency of type I IFN receptor in lupus-prone New Zealand mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease. J Immunol 2009; 183:6021-9; PMID:19812195; http://dx.doi.org/10.4049/jimmunol.0803872
   PubMed Web of Science ®Google Scholar
• Kirou KA, Gkrouzman E. Anti-interferon alpha treatment in SLE. Clin Immunol 2013; 148:303-12; PMID:23566912; http://dx.doi.org/10.1016/j.clim.2013.02.013
   PubMed Web of Science ®Google Scholar
• Kalie E, Jaitin DA, Podoplelova Y, Piehler J, Schreiber G. The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities. J Biol Chem 2008; 283:32925-36; PMID:18801736; http://dx.doi.org/10.1074/jbc.M806019200
   PubMed Web of Science ®Google Scholar
• Thomas C, Moraga I, Levin D, Krutzik PO, Podoplelova Y, Trejo A, Lee C, Yarden G, Vleck SE, Glenn JS, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011; 146:621-32; PMID:21854986; http://dx.doi.org/10.1016/j.cell.2011.06.048
   PubMed Web of Science ®Google Scholar
• Ouyang S, Gong B, Li JZ, Zhao LX, Wu W, Zhang FS, Sun L, Wang SJ, Pan M, Li C, et al. Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus. J Mol Med (Berl) 2012; 90:837-46; PMID:22307521; http://dx.doi.org/10.1007/s00109-012-0866-3
   PubMed Web of Science ®Google Scholar
• Smith K, Crowe SR, Garman L, Guthridge CJ, Muther JJ, McKee E, Zheng NY, Farris AD, Guthridge JM, Wilson PC, et al. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization. Vaccine 2012; 30:4276-83; PMID:22425791; http://dx.doi.org/10.1016/j.vaccine.2012.03.002
   PubMed Web of Science ®Google Scholar
• Pascual V, Farkas L, Banchereau J. Systemic lupus erythematosus: all roads lead to type I interferons. Curr Opin Immunol 2006; 18:676-82; PMID:17011763; http://dx.doi.org/10.1016/j.coi.2006.09.014
   PubMed Web of Science ®Google Scholar
• Becker-Merok A, Ostli-Eilersten G, Lester S, Nossent J. Circulating interferon- 2 levels are increased in the majority of patients with systemic lupus erythematosus and are associated with disease activity and multiple cytokine activation. Lupus 2012; 22:155-63; PMID:23213068; http://dx.doi.org/10.1177/0961203312468964
   PubMed Web of Science ®Google Scholar
• Theofilopoulos AN, Baccala R, Beutler B, Kono DH. Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005; 23:307-36; PMID:15771573; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115843
   PubMed Web of Science ®Google Scholar
• Strunk JJ, Gregor I, Becker Y, Li Z, Gavutis M, Jaks E, Lamken P, Walz T, Enderlein J, Piehler J. Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain. J Mol Biol 2008; 377:725-39; PMID:18294654; http://dx.doi.org/10.1016/j.jmb.2008.01.017
   PubMed Web of Science ®Google Scholar
• Lamken P, Gavutis M, Peters I, Van der Heyden J, Uze G, Piehler J. Functional cartography of the ectodomain of the type I interferon receptor subunit ifnar1. J Mol Biol 2005; 350:476-88; PMID:15946680; http://dx.doi.org/10.1016/j.jmb.2005.05.008
   PubMed Web of Science ®Google Scholar
• Kalunian K, Merrill JT, Maciuca R, Ouyang WJ, McBride JM, Townsend MJ, Park E, Li J, Wei X, Morimoto A, et al. Efficacy and Safety of Rontalizumab (Anti-Interferon Alpha) in SLE Subjects with Restricted Immunosuppressant Use: Results of A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study. Arthritis Rheum 2012; 64:S1111-S; http://dx.doi.org/10.1002/art.34669
   Google Scholar
• Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha Induces Early Lethal Lupus in Preautoimmune (New Zealand Black x New Zealand White)F1 but Not in BALB/c Mice. J Immunol 2005; 174:2499-506; PMID:15728455; http://dx.doi.org/10.4049/jimmunol.174.5.2499
   PubMed Web of Science ®Google Scholar
• Yu R, Wang S, Yu YZ, Du WS, Yang F, Yu WY, Sun ZW. Neutralizing antibodies of botulinum neurotoxin serotype A screened from a fully synthetic human antibody phage display library. J Biomol Screen 2009; 14:991-8; PMID:19726786; http://dx.doi.org/10.1177/1087057109343206
   PubMed Web of Science ®Google Scholar
• Chen R, Weng Z. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 2002; 47:281-94; PMID:11948782; http://dx.doi.org/10.1002/prot.10092
   PubMed Web of Science ®Google Scholar
• Li LCR, Weng ZP. RDOCK: Refinement of rigid-body protein docking predictions. Proteins 2003; 53:693-707; PMID:14579360; http://dx.doi.org/10.1002/prot.10460
   PubMed Web of Science ®Google Scholar
• Schymkowitz J, Borg J, Stricher F, Nys R, Rousseau F, Serrano L. The FoldX web server: an online force field. Nucleic Acids Res 2005; 33:W382-8; PMID:15980494; http://dx.doi.org/10.1093/nar/gki387
   PubMed Web of Science ®Google Scholar
• Nacionales DC, Kelly KM, Lee PY, Zhuang H, Li Y, Weinstein JS, Sobel E, Kuroda Y, Akaogi J, Satoh M, et al. Type I interferon production by tertiary lymphoid tissue developing in response to 2,6,10,14-tetramethyl-pentadecane (pristane). Am J Pathol 2006; 168:1227-40; PMID:16565497; http://dx.doi.org/10.2353/ajpath.2006.050125
   PubMed Web of Science ®Google Scholar
• Lee PY, Weinstein JS, Nacionales DC, Scumpia PO, Li Y, Butfiloski E, van Rooijen N, Moldawer L, Satoh M, Reeves WH. A Novel Type I IFN-Producing Cell Subset in Murine Lupus. J Immunol 2008; 180:5101-8; PMID:18354236; http://dx.doi.org/10.4049/jimmunol.180.7.5101
   PubMed Web of Science ®Google Scholar